1. Academic Validation
  2. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth

Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth

  • Cancer Res. 2011 Jan 1;71(1):197-205. doi: 10.1158/0008-5472.CAN-10-1282.
Jo Waaler 1 Ondrej Machon Jens Peter von Kries Steven Ray Wilson Elsa Lundenes Doris Wedlich Dietmar Gradl Jan Erik Paulsen Olga Machonova Jennifer L Dembinski Huyen Dinh Stefan Krauss
Affiliations

Affiliation

  • 1 Section for Cellular and Genetic Therapy, Institute of Microbiology, Oslo University Hospital, and Norwegian Center for Stem Cell Research, Forskningsparken, Oslo, Norway. jo.waaler@rr-research.no
Abstract

Canonical Wnt signaling is deregulated in several types of human Cancer where it plays a central role in tumor cell growth and progression. Here we report the identification of 2 new small molecules that specifically inhibit canonical Wnt pathway at the level of the destruction complex. Specificity was verified in various cellular reporter systems, a Xenopus double-axis formation assay and a gene expression profile analysis. In human colorectal Cancer (CRC) cells, the new compounds JW67 and JW74 rapidly reduced active β-catenin with a subsequent downregulation of Wnt target genes, including AXIN2, SP5, and NKD1. Notably, AXIN2 protein levels were strongly increased after compound exposure. Long-term treatment with JW74 inhibited the growth of tumor cells in both a mouse xenograft model of CRC and in APC(Min) mice (multiple intestinal neoplasia, Min). Our findings rationalize further preclinical and clinical evaluation of these new compounds as novel modalities for Cancer treatment.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-19739
    99.34%, Wnt Antagonist
    Wnt
  • HY-108442
    98.15%, Wnt Signaling Inhibitor
    Wnt